New drug combo shows promise in preventing transplant complications
NCT ID NCT03605927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cells attack the patient's body. The main goal was to see how many patients developed moderate to severe GVHD within 100 days after transplant. This is a phase 1 trial focused on safety and early effectiveness, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
- Could a walk a day keep brain fog away after a stem cell transplant?